RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 129 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $124,819 | +1.2% | 84,337 | -0.9% | 0.00% | -100.0% |
Q4 2023 | $123,338 | +33.7% | 85,061 | -0.4% | 0.00% | 0.0% |
Q3 2023 | $92,236 | -13.2% | 85,404 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $106,256 | -3.4% | 82,369 | -1.1% | 0.00% | 0.0% |
Q1 2023 | $109,941 | -10.2% | 83,289 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $122,447 | +26.2% | 81,631 | -0.4% | 0.00% | 0.0% |
Q3 2022 | $97,000 | +6.6% | 81,929 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $91,000 | -64.2% | 80,771 | -4.8% | 0.00% | 0.0% |
Q1 2022 | $254,000 | +5.4% | 84,827 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $241,000 | -28.9% | 90,798 | -2.9% | 0.00% | -50.0% |
Q3 2021 | $339,000 | -18.3% | 93,515 | -2.3% | 0.00% | +100.0% |
Q2 2021 | $415,000 | +22.4% | 95,737 | -3.3% | 0.00% | 0.0% |
Q1 2021 | $339,000 | -2.0% | 99,037 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $346,000 | +41.8% | 98,776 | -2.8% | 0.00% | 0.0% |
Q3 2020 | $244,000 | +28.4% | 101,610 | -2.2% | 0.00% | 0.0% |
Q2 2020 | $190,000 | +22.6% | 103,921 | +4.4% | 0.00% | 0.0% |
Q1 2020 | $155,000 | -31.1% | 99,580 | -5.5% | 0.00% | 0.0% |
Q4 2019 | $225,000 | +13.1% | 105,335 | -0.8% | 0.00% | 0.0% |
Q3 2019 | $199,000 | -28.7% | 106,220 | -0.7% | 0.00% | 0.0% |
Q2 2019 | $279,000 | +1.5% | 106,961 | -0.1% | 0.00% | 0.0% |
Q1 2019 | $275,000 | +8.3% | 107,062 | -3.1% | 0.00% | 0.0% |
Q4 2018 | $254,000 | -29.1% | 110,532 | -0.8% | 0.00% | 0.0% |
Q3 2018 | $358,000 | +17.8% | 111,383 | +3.6% | 0.00% | 0.0% |
Q2 2018 | $304,000 | -9.3% | 107,493 | +13.7% | 0.00% | 0.0% |
Q1 2018 | $335,000 | -13.4% | 94,555 | -5.1% | 0.00% | 0.0% |
Q4 2017 | $387,000 | +83.4% | 99,640 | +20.2% | 0.00% | 0.0% |
Q3 2017 | $211,000 | +1.0% | 82,884 | +8.1% | 0.00% | 0.0% |
Q2 2017 | $209,000 | -15.7% | 76,687 | +2.4% | 0.00% | 0.0% |
Q1 2017 | $248,000 | +95.3% | 74,900 | +39.9% | 0.00% | – |
Q4 2016 | $127,000 | -99.9% | 53,555 | -0.3% | 0.00% | -100.0% |
Q3 2016 | $197,053,000 | +64.8% | 53,693 | +0.2% | 0.00% | 0.0% |
Q2 2016 | $119,553,000 | +11.7% | 53,611 | +3.8% | 0.00% | – |
Q1 2016 | $107,000,000 | -31.4% | 51,624 | 0.0% | 0.00% | -100.0% |
Q4 2015 | $156,000,000 | +121775.0% | 51,624 | -0.2% | 0.00% | 0.0% |
Q3 2015 | $128,000 | -99.9% | 51,714 | +0.1% | 0.00% | 0.0% |
Q2 2015 | $165,806,000 | -16.7% | 51,653 | -7.3% | 0.00% | 0.0% |
Q1 2015 | $198,931,000 | +59.2% | 55,723 | +1.2% | 0.00% | 0.0% |
Q4 2014 | $124,939,000 | +12.6% | 55,039 | -3.8% | 0.00% | – |
Q3 2014 | $110,997,000 | -46.6% | 57,215 | -0.1% | 0.00% | -100.0% |
Q2 2014 | $207,847,000 | -9.6% | 57,258 | -3.4% | 0.00% | 0.0% |
Q1 2014 | $229,906,000 | +39.5% | 59,254 | +2.5% | 0.00% | 0.0% |
Q4 2013 | $164,818,000 | -21.2% | 57,831 | -1.0% | 0.00% | 0.0% |
Q3 2013 | $209,115,000 | +6.6% | 58,412 | -0.6% | 0.00% | 0.0% |
Q2 2013 | $196,182,000 | – | 58,737 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |